Adjuvant CMFVP Versus Adjuvant CMFVP Plus Ovariectomy for Premenopausal, Node-Positive, and Estrogen Receptor - Positive Breast Cancer Patients: A Southwest Oncology Group Study

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 46-51

  Rivkin, Saul E ^a   Green, Stephanie ^a   O'Sullivan, Janet ^a   Cruz, Anatolio B ^a   Abeloff, Martin D ^a   Jewell, William R ^a   Costanzi, John J ^a   Farrar, William B ^a   Osborne, C Kent ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; MELPHALAN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; ALOPECIA; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; NAUSEA; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PARESTHESIA; PERIPHERAL NEUROPATHY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; OVARIECTOMY; PREDNISONE; PREMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; SURVIVAL RATE; VINCRISTINE;

EID: 0030067826     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.46     Document Type: Article

References (16)

1. McGuire WL: Current status of estrogen receptor in human breast cancer. Cancer 36:638-644, 1975
2. Knight W, Livingston R, Gregory E, et al: Estrogen receptor: An independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669-4671, 1977
3. Fisher B, Fisher ER, Redmond C: Ten-year results from the NSABP clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4:929-941, 1986
4. Bonadonna G, Valagussa P, Rossie A, et al: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5:95-115, 1985
5. Rivkin SE, Green S, Metch B, et al: Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group study. J Clin Oncol 7:1229-1238, 1989
6. Veronesi U, Pizzocaro G, Rossi A: Oophorectomy for advanced carcinoma of the breast. Surg Gynecol Obstet 141:569-570, 1975
7. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. IND 10:239-253, 1992
8. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
9. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
10. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
11. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-84, 1992
12. Meakin JW, Allt WEC, Beale FA, et al: Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat 3:45-48, 1983
13. Cole MP: A clinical trial of an artificial menopause in carcinoma of the breast, in Maner M, Lalanne CM (eds): Hormones and Breast Cancer, vol 55. Paris, France, INSERM, 1975, pp 143-150
14. International Breast Cancer Study Group: Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. Ann Oncol 1:30-35, 1990
15. Scottish Cancer Trials Breast Group and ICRF Breast Unit: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Lancet 341:1293-1298, 1993
16. Brincker H, Rose C, Rank F, et al: Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol 5:1771-1778, 1987